BioGenCell’s groundbreaking therapy reaches Israel’s national newspaper “Israel Today”

November 12, 2017

With the approval of the Regulatory Authorities in both Israel and Europe, BioGenCell has entered Phase I/II of first in human clinical trials being conducted in the Sanz Medical Center, Laniado Hospital. Results from the first cohort of patients show that the treatment is safe and has therapeutic effects in both objective outcomes, including limb salvage, leg blood flow and wound healing and subjective outcomes including walking ability, reduction of pain and improved quality of life.

Israel’s national newspaper “Israel Today” summarizes BioGenCell’s latest clinical trial at Laniado Hospital in Hebrew below:

Article in Israel Today-6Oct17




Latest article on BioGenCell’s cell therapy is printed in the textbook “Vascular Surgery” edited by Alan Dardik

June 20, 2017

BioGenCell’s latest article on its innovative cell therapy was published in the renowned textbook “Vascular Surgery: A Global Perspective” edited by Alan Dardik.Porat 2017. Cell Therapy for Vascular. in Dardik Text Book

Dr. Yael Porat and her colleagues wrote a full chapter in the textbook which describes among other things the method and rationale behind BioGenCell’s clinical trial.

The textbook provides the first review and comparison of the diversity of vascular surgery practice around the world and includes chapters written by worldwide expert specialists, each discussing their local approach to a common vascular disease and its treatment.

book cover

Dr. Porat takes part in this year’s Israeli Entrepreneur Week

March 23, 2017

Dr. Porat took part in this year’s Israeli Entrepreneur Week (Yazamut On the Bar) where high-tech and biotech companies are encouraged to speak to a young audience in bars or pubs and tell their story. Dr. Porat told her personal story to a full house in a Tel-Aviv bar inspiring both young and old to never give up on their dreams in her lecture “Behind the Scenes of Tomorrow’s Medicine- Your Own Blood is Your Best Medicine Cabinet.”


BioGenCell participates in a number of world- renowned conferences throughout 2017:

March 23, 2017

  • Dr. Galit Sivak, MD, Director of Vascular Surgery, Rabin Medical Center and Co-PI of  BioGenCell’s  study together with Dr. Yael Porat presented the promising results of our first five patients in the ICI Meeting on the 5th of December 2016.
  • Dr. Porat presented the results of our clinical trial at the Global Investor Forum Maastricht, the Netherlands 8-9 Feb 2017 – an opportunity for Israeli startups in RegMed and MedTech. The Global Investor Forum exposes promising biomed Start-Ups and joins the powerful global BIOMED network of the world’s leading investors, entrepreneurs, corporates and key physicians. The focus was on Regenerative Medicine and Medical Devices.
  • Dr. Yael Porat lectured at the 8th World Congress and Exposition on Cell & Stem Cell Research, March 20-22, 2017 Orlando, Florida, USA. year’s conference focused on exploring and exploiting novel techniques in Cellular and Stem Cell Research.
  • Dr. Michael Frogel, an Associate Professor of Pediatrics at the Albert Einstein College of Medicine, Principal Investigator for the New York City Pediatric Disaster Coalition (PDC), Medical Director of the Pediatric Disaster Mental Health Initiative at Maimonides Medical Center and BioGenCell’s  medical advisor, presented the results of the company’s first cohort of patients at the renowned Veith Symposium. Prof. Veith, who is also a member of BioGenCell’s scientific advisory board, held his annual conference this year in November.



BioGenCell wins an EU competitive grant of over one million Euro.

March 23, 2017

BioGenCell has won an EU competitive grant this year (2017) of over one million Euro. This prestigious DGO6 grant was given by the Belgium Authorities in the Wallonia region of Belgium and will be used to further our studies and clinical trial in collaboration with the CHU hospital and scientific team in Liege.

BioGenCell’s first in-human clinical trial has begun!

March 23, 2017

BioGenCell’s first in-human clinical trial has begun. The company is performing a Phase I/II clinical trial in CLI patients ( Identifier: NCT02805023).This study is being conducted at the Laniado Hospital, headed by Dr. Mark J Niven, a worldwide leader in the field of diabetes and the Director of the Endocrine and Diabetes Unit, incorporating the Bildirici Center for Diabetes Care and Research. This disease is the most serious form of peripheral vascular disease (PVD) and is the direct cause of limb amputations, as well as significant patient morbidity and mortality.

We have now finished our first five patients with promising results showing that the therapy is safe and leads to substantial improvements for patients suffering from Critical Limb Ischemia (CLI). Our goal beyond elimination of amputations is to extend lifespan and improve functionality and quality of life in our patients. We look forward to continuing with our next 25 patients to conclusively prove the concept behind this technology.

BioGenCell presented at TEDxJerusalem April 15, 2015

May 25, 2015

BioGenCell presented at TEDxJerusalem April 15, 2015

The future of medicine is here today. Dr. Yael Porat, CEO of BioGenCell (, describes the development of a groundbreaking technology for the automated production of personalized stem-cell therapies. These products, derived from the patient’s own blood, will be available on demand within 24 hours, to save lives and restore the quality of life for the billion people worldwide with blood vessel diseases including heart disease, stroke, PAD and dementia.

September 2014: BioGenCell receives a startup grant from Pace University Lubin School of Business in association with the MIT Enterprise Forum for Israel.

April 28, 2015

BioGenCell receives grant from Pace University Lubin School of Business/ MIT Enterprise Forum for Israel

A $250,000 grant from Philanthropist Michael Dezer will provide Pace students from a variety of disciplines the opportunity to work closely with entrepreneurs from Israel while assisting their companies business development.  Six student fellows will be chosen to provide research, analysis, product testing, and additional support to two Israel-based companies that have been selected to participate in the program.  Through working with the partner companies, BioGenCell Ltd. and FreshBiz, not only will the students earn a stipend, but they will have the unique opportunity to closely interact with the business leadership teams, thus gaining valuable insights and real-world experience. The Pace entrepreneurship Lab implemented this initiative in association with the MIT Enterprise forum of IsraelThe Forum and its associated chapters in 28 countries comprise a global non-profit organization dedicated to promoting the growth and success of high-tech entrepreneurial ventures by connecting ideas, technology and people.


US Patent US8956870 COM Method for using directing cells for specific stem/progenitor cell activation and differentiation – Issued Feb 2015

April 17, 2015

BioGenCell selected as finalist for the ICI2014 Innovation Award. Dec 14, 2014

April 17, 2015

Dr. Porat Presents BioGenCell at the ICI Innovation Awards 2014

Next Page »